Akili Interactive
received FDA authorization for EndeavorOTC in June 2024, the first FDA clearance of a digital treatment for adult ADHD delivered through a video game, and launched ENDEAVORRIDE in Japan with Shionogi in June 2026 as the first adjunctive therapy app for pediatric ADHD in that market.
- Country
- United States
- Ticker
- AKLI
FDA cleared
ADHD treatment
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Digital therapeutics | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.